Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise

被引：0
|
作者：
Ying Hu [1 ]
Huimin Zou [2 ]
Yang Shen [3 ]
Qi Ni [4 ]
Yijun Li [1 ]
Hao Zhang [1 ]
Xianwen Chen [5 ]
Carolina Oi Lam Ung [2 ]
Hao Hu [2 ]
Yiming Mu [6 ]
机构：
[1] PLA General Hospital,Department of Endocrinology, First Medical Center of Chinese
[2] University of Macau,State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences
[3] Peking University,School of Public Health
[4] Peking University,China Center for Health Development Studies
[5] Novo Nordisk (China) Pharmaceuticals Co.,Centre for Pharmaceutical Regulatory Sciences
[6] Ltd.,Department of Public Health and Medicinal Administration, Faculty of Health Sciences
[7] University of Macau,undefined
[8] University of Macau,undefined
来源：
Diabetes Therapy | 2025年 / 16卷 / 5期
关键词：
Type 2 diabetes; Semaglutide; Dulaglutide; Cost-effectiveness analysis; China;
D O I：
10.1007/s13300-025-01716-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：915 / 929
页数：14
相关论文
共 50 条
  • [31] Cost-effectiveness of once-weekly semaglutide versus empagliflozin in people with type 2 diabetes and inadequate glycaemic control in Sweden
    Londahl, M.
    Nihlberg, K.
    Ericsson, A.
    DIABETOLOGIA, 2019, 62 : S399 - S399
  • [32] CEA OF ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE VERSUS DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES WITH INADEQUATE GLYCEMIC CONTROL IN CHINA
    Zhen, R.
    Ung, C. O. L.
    Shen, Y.
    Zou, H.
    Xue, Y.
    Wang, Y.
    Hu, H.
    VALUE IN HEALTH, 2022, 25 (07) : S368 - S368
  • [33] COST UTILITY ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE AND DULAGLUTIDE FOR PATIENTS WITH TYPE 2 DIABETES IN SAUDI ARABIA
    Hassan, M.
    Barham, L.
    VALUE IN HEALTH, 2023, 26 (12) : S54 - S54
  • [34] Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Persson, Sofie
    Grip, Emilie Toresson
    DIABETES, 2018, 67
  • [35] Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
    Arslanian, Silva A.
    Hannon, Tamara
    Zeitler, Philip
    Chao, Lily C.
    Boucher-Berry, Claudia
    Barrientos-Perez, Margarita
    Bismuth, Elise
    Dib, Sergio
    Cho, Jang Ik
    Cox, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (05): : 433 - 443
  • [36] A COST OF CONTROL ANALYSIS OF ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE VERSUS DULAGLUTIDE FOR BRINGING PATIENTS TO TREATMENT TARGETS IN CHINA
    Zhen, R.
    Gu, Z.
    Shen, Y.
    Chen, L.
    VALUE IN HEALTH, 2022, 25 (07) : S350 - S350
  • [37] Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes
    Senoo, Yuki
    Kami, Masahiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (16): : 1529 - 1530
  • [38] A Long-term Cost-Effectiveness Analysis of Treatments for Type 2 Diabetes in Portugal: Once-Weekly Semaglutide 1 mg Versus Once-Daily Empagliflozin 25 mg
    Carvalho, Davide
    Costa, Catarina
    Hallen, Nino
    Baker-Knight, James
    Hunt, Barnaby
    REVISTA PORTUGUESA DE ENDOCRINOLOGIA DIABETES E METABOLISMO, 2021, 16 (1-2) : 13 - 20
  • [39] A LONG-TERM COST-EFFECTIVENESS ANALYSIS OF TREATMENTS FOR TYPE 2 DIABETES IN PORTUGAL: ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS ONCE-DAILY EMPAGLIFLOZIN 25 MG
    Hallen, N.
    Carvalho, D.
    Costa, C.
    Hunt, B.
    VALUE IN HEALTH, 2020, 23 : S510 - S510
  • [40] The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
    Viljoen, Adie
    Chubb, Barrie
    Malkin, Samuel J. P.
    Berry, Sasha
    Hunt, Barnaby
    Bain, Stephen C.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (06): : 895 - 907
12345